Suchitra Pilli, MD
Pulmonary Disease · Scottsdale, AZNPI 1750649844
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (42.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Intuitive Surgical at 59.2% of the total. Reporting peaked in 2023 at $23,361 and has fallen 69.5% since, to $7,124 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $215.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$22K
- Ambu Inc.$10K
- Pulmonx Corporation$1K
- AstraZeneca$930
- Noah Medical Corporation$323
- Galvanize Therapeutics, Inc$322
- plus $2K from 32 others
What the payments were for
- Consulting fees$9,83326%
- Speaking & faculty fees$6112%
- Travel & lodging$4,20711%
- Food & beverage$7,27619%
- Education$16,00042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 38 | $22,468 |
| Ambu Inc. | 6 | $10,273 |
| Pulmonx Corporation | 27 | $1,183 |
| AstraZeneca(2 entities) | 27 | $930 |
| Noah Medical Corporation | 1 | $323 |
| Galvanize Therapeutics, Inc | 5 | $322 |
| Grifols USA, LLC | 8 | $237 |
| Boston Scientific | 5 | $223 |
| Boehringer Ingelheim | 8 | $221 |
| Regeneron Healthcare Solutions, Inc. | 3 | $164 |
| Steris Corporation | 1 | $158 |
| Siemens Medical Solutions USA, Inc. | 2 | $141 |
| Novo Nordisk | 1 | $125 |
| BD | 3 | $111 |
| Genentech USA, Inc. | 1 | $106 |
| Serpex Medical Inc | 1 | $93 |
| Davol Inc. | 2 | $92 |
| Pinnacle Biologics, Inc | 1 | $78 |
| Johnson & Johnson(2 entities) | 3 | $65 |
| Amgen | 3 | $58 |
| GSK | 5 | $56 |
| United Therapeutics Corporation | 3 | $56 |
| Edwards Lifesciences | 1 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $38 |
| Melinta Therapeutics, LLC | 3 | $38 |
| Bayer | 2 | $38 |
| Zimmer Biomet | 1 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Merit Medical Systems Inc | 1 | $18 |
| Harmony Biosciences LLC | 1 | $17 |
| Sandoz | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Sanofi | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$18,591
- ION$3,000
- ZEPHYR ENDOBRONCHIAL VALVE$786
- CHARTIS CATHETER$607
- ZEPHYR DELIVERY CATHETER$607
- PULMONX CHARTIS TABLET CONSOLE$607
- GALAXY$323
- ALIYA SYSTEM$238
- FASENRA$219
- LIBTAYO$135
- BREZTRI$125
- Ozempic$125
- SYMBICORT$107
- BREZTRI AEROSPHERE$107
- Prolastin-C Liquid$101
How this compares
$37,927 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $56,877 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $18,468 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $15,021 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $3,891 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,162 |
| Montelukast Sodium | 25 | $137 |
| Methylprednisolone | 11 | $66 |
| Azithromycin | 14 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $56 | $79,237115 claims |
| AstraZenecaBreztri Aerosphere | $930 | $15,02120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Scottsdale
- Laszlo VaszarScottsdale$18K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Richard SueGilbert$224K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.